company mission
ImmuneBridge's mission did not meaningfully change between the February 8, 2023 and January 6, 2024 snapshots. In both, the company says it wants to eliminate cancer by building allogeneic cell therapies that make curative treatment broadly accessible. The scientific core also stays fixed: cord blood-derived immune stem cell expansion, preservation of immune multipotency, and an initial focus on NK cell-based immunotherapy. What changed is mostly phrasing. "Cellular medicines" became "cell therapies," and the platform description shifted from a more product-like framing to a more technology-like one, with "proprietary expansion technology" and "amplifies" replacing some of the earlier platform language. Those edits read like positioning cleanup, not a strategic turn. The evidence is thin because we only have two website snapshots, and they are extremely close in substance. Based on these statements alone, the company's belief about its mission looks stable: same disease target, same access claim, same cell source, same multipotency argument, same NK-first starting point. If anything evolved here, it was copywriting discipline, not company direction.